EA201391725A1 - Способ лечения немелкоклеточного рака легкого - Google Patents

Способ лечения немелкоклеточного рака легкого

Info

Publication number
EA201391725A1
EA201391725A1 EA201391725A EA201391725A EA201391725A1 EA 201391725 A1 EA201391725 A1 EA 201391725A1 EA 201391725 A EA201391725 A EA 201391725A EA 201391725 A EA201391725 A EA 201391725A EA 201391725 A1 EA201391725 A1 EA 201391725A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lung cancer
nucleotides
little
treatment
cell lung
Prior art date
Application number
EA201391725A
Other languages
English (en)
Inventor
Чен Дуксин
Шоши Тесслер
Мартин Глив
Original Assignee
Тева Фармасьютикал Индастриз Лтд.
Дзе Юниверсити Оф Бритиш Коламбиа
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47177396&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201391725(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Тева Фармасьютикал Индастриз Лтд., Дзе Юниверсити Оф Бритиш Коламбиа filed Critical Тева Фармасьютикал Индастриз Лтд.
Publication of EA201391725A1 publication Critical patent/EA201391725A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Способ лечения больного человека, страдающего раком легкого, включающий периодическое введение больному человеку химиотерапевтических средств, содержащих количество таксана и 640 мг олигонуклеотида против кластерина с последовательностью CAGCAGCAGAGTCTTCATCAT (SEQ ID NO:1), где олигонуклеотид против кластерина имеет на всем протяжении фосфоротиоатный остов, имеет части сахаров нуклеотидов 1-4 и 18-21, несущие 2'-О-метоксиэтильные модификации, имеет нуклеотиды 5-17, которые представляют собой 2'-дезоксинуклеотиды, и имеет 5-метилцитозины в нуклеотидах 1, 4 и 19, в результате чего осуществляется лечение больного человека, страдающего раком легкого.
EA201391725A 2011-05-19 2012-05-18 Способ лечения немелкоклеточного рака легкого EA201391725A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161487918P 2011-05-19 2011-05-19
US201161493346P 2011-06-03 2011-06-03
PCT/IB2012/001085 WO2012156817A2 (en) 2011-05-19 2012-05-18 Method for treating non-small cell lung cancer

Publications (1)

Publication Number Publication Date
EA201391725A1 true EA201391725A1 (ru) 2014-05-30

Family

ID=47177396

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391725A EA201391725A1 (ru) 2011-05-19 2012-05-18 Способ лечения немелкоклеточного рака легкого

Country Status (16)

Country Link
US (1) US20130017272A1 (ru)
EP (1) EP2709673A4 (ru)
JP (1) JP2014520081A (ru)
KR (1) KR20140034838A (ru)
CN (1) CN103958681A (ru)
AR (1) AR086514A1 (ru)
AU (1) AU2012257487A1 (ru)
CA (1) CA2836676A1 (ru)
CL (1) CL2013003324A1 (ru)
EA (1) EA201391725A1 (ru)
IL (1) IL227720A0 (ru)
MX (1) MX2013013384A (ru)
PE (1) PE20140647A1 (ru)
SG (1) SG194931A1 (ru)
WO (1) WO2012156817A2 (ru)
ZA (1) ZA201309254B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU767133B2 (en) 1999-02-26 2003-10-30 University Of British Columbia, The TRPM-2 antisense therapy
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
KR20140038388A (ko) 2011-03-15 2014-03-28 더 유니버시티 오브 브리티쉬 콜롬비아 전립선암의 치료를 위한 항-클러스테린 올리고뉴클레오타이드와 hsp90 저해제의 병용
UY34812A (es) * 2012-05-18 2013-12-31 Teva Pharma Método para el tratamiento del cáncer de pulmón de células no pequeñas
CA2900533A1 (en) * 2013-03-14 2014-10-02 Oncogenex Technologies Inc. Anti-clusterin monotherapy for cancer treatment
CA2903239A1 (en) * 2013-03-14 2014-10-02 Oncogenex Technologies Inc. Custirsen treatment with reduced toxicity
US20160324439A1 (en) * 2015-05-06 2016-11-10 Taiwan Textile Research Institute Stereoscopic conductive fabric and module for detecting electrical signals from body skin applying the same
WO2016191751A1 (en) * 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
EP3302502B1 (en) * 2015-05-29 2019-08-28 Dynavax Technologies Corporation Intrapulmonary administration of polynucleotide toll-like receptor 9 agonists for treating cancer of the lung
KR20190115505A (ko) 2018-03-15 2019-10-14 특허법인 해담 기업 맞춤형 후속 개발 아이템 발굴 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
WO2003062421A1 (en) * 2002-01-17 2003-07-31 The University Of British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
US8710020B2 (en) * 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
EP1789460B1 (en) * 2004-09-02 2013-01-09 Isis Pharmaceuticals, Inc. Polymeric beads for oligonucleotide synthesis

Also Published As

Publication number Publication date
MX2013013384A (es) 2014-06-11
KR20140034838A (ko) 2014-03-20
CN103958681A (zh) 2014-07-30
EP2709673A2 (en) 2014-03-26
AR086514A1 (es) 2013-12-18
CL2013003324A1 (es) 2014-08-01
AU2012257487A1 (en) 2014-01-16
JP2014520081A (ja) 2014-08-21
CA2836676A1 (en) 2012-11-22
ZA201309254B (en) 2015-05-27
SG194931A1 (en) 2013-12-30
EP2709673A4 (en) 2014-12-17
WO2012156817A3 (en) 2013-02-21
PE20140647A1 (es) 2014-06-05
US20130017272A1 (en) 2013-01-17
WO2012156817A2 (en) 2012-11-22
IL227720A0 (en) 2013-09-30
WO2012156817A9 (en) 2013-01-03

Similar Documents

Publication Publication Date Title
EA201391725A1 (ru) Способ лечения немелкоклеточного рака легкого
PH12014502569A1 (en) Method for treating non-small cell lung cancer
US10184151B2 (en) Micrornas in neurodegenerative disorders
NZ630914A (en) Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
MX2013009191A (es) Oligonucleotidos antisentido.
JP2013529909A5 (ru)
RU2014101547A (ru) Апоптоз-индуцирующее средство
RU2013148024A (ru) Композиции и способы ингибирования экспрессии гена tmprss6
MX2018012038A (es) Agentes de iarn modificados.
EA201490563A1 (ru) Антисмысловые олигонуклеотиды для лечения врожденного амавроза лебера
EA202090338A1 (ru) Функционально-модифицированные олигонуклеотиды и их субъединицы
NZ603901A (en) Vectors and sequences for the treatment of diseases
JP2015514778A5 (ru)
TN2015000079A1 (en) Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
RU2013102545A (ru) Связывающая vegfa си-рнк и способы лечения in vivo
NZ700902A (en) Lowering saturated fatty acid content of plant seeds
WO2013088338A1 (en) Micrornas and uses therof
NZ741841A (en) Antisense oligonucleotides for use in treating alzheimer’s disease
RU2013121802A (ru) Профилактический или терапевтический агент для лечения фиброза
AR091327A1 (es) DISEÑO DE ARNhc BIFUNCIONAL EN EL SARCOMA DE EWING
RU2016131028A (ru) Композиции, содержащие асимметричную интерферирующую рнк, которые подвергают сайленсингу k-ras, и способы их применения
WO2011087343A3 (ko) Ｈｐｖ 감염과 관련된 암의 치료용 조성물
WO2012131673A3 (en) Ccat-1 silencing nucleic acid agents for treating cancer
Philip et al. Mechanistic role of let-7c in breast cancer cell activity
MX2008016104A (es) Terapia génica mediante silenciamiento del gen wt1 con secuencias de rnas de interferencia a través de polietilenamina administrados via aerosol para cancer pulmonar.